The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Targeting mutant CALR in MF and ET: the therapeutic potential of INCA33989
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, comments on the therapeutic potential of INCA33989, a CALR-specific monoclonal antibody for the treatment of myelofibrosis (MF) and essential thrombocythemia (ET). Dr Mascarenhas highlights promising preclinical and clinical results, with significant effects in reducing mutant CALR-bearing hematopoietic stem and progenitor cells. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
